Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Adicet BioLTS:0HX7 +0.12%31 EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus rates LTS:0HX7 with a GF Score™ of 31/100 and a GF Value™ of $0.44 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 942 Biotechnology companies, Adicet Bio ranks worse than 106157.01% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Adicet Bio's EBITDA for the
three
months ended in Mar. 2026 was $-18.88 Mil. Adicet Bio's Revenue for the
three
months ended in Mar. 2026 was $0.00 Mil. Therefore, Adicet Bio's EBITDA margin for the quarter that ended in Mar. 2026 was 0.00%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Adicet Bio EBITDA Margin % Related Terms
Adicet Bio EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Adicet Bio's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0HX7 vs ATRA, PYPD, GANX: EBITDA Margin % Comparison
For the Biotechnology subindustry, Adicet Bio's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adicet Bio EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Adicet Bio's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Adicet Bio's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adicet Bio (LTS:0HX7) has a EBITDA Margin % of 0.00% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Adicet Bio and its competitors. According to the industry distribution chart, Adicet Bio ranks #999999 out of 942 companies in the Biotechnology industry.
Is Adicet Bio's EBITDA Margin % too high?
Adicet Bio's current EBITDA Margin % is 0.00%. Based on the distribution chart, Adicet Bio ranks #999999 out of 942 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Adicet Bio has a GF Score™ of 31/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Adicet Bio's EBITDA Margin % compare to ATRA and PYPD?
According to the Biotechnology industry distribution chart, Adicet Bio ranks #999999 out of 942 companies for EBITDA Margin %. This places Adicet Bio in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Adicet Bio and its competitors. Adicet Bio's current EBITDA Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adicet Bio stock overvalued right now?
Based on GuruFocus' analysis, Adicet Bio (LTS:0HX7) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.44, compared to a current price of $8.66 — trading 1868.2% above its estimated fair value. The current EBITDA Margin % is 0.00%. Adicet Bio's overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Adicet Bio (LTS:0HX7), the current EBITDA Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Adicet Bio (LTS:0HX7) Overvalued in 2026?
Based on GuruFocus' analysis, Adicet Bio stock appears to be overvalued.
The current stock price of $8.66 is trading 1868.2% above its estimated GF Value™ of $0.44.
GuruFocus considers Adicet Bio to be Significantly Overvalued.
Key valuation signals for LTS:0HX7:
EBITDA Margin %: 0.00%
GF Value™: $0.44 vs. price of $8.66 (1868.2% above fair value)
No single metric tells the full story. See the LTS:0HX7 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).
31GF Score
Get the complete analysis for LTS:0HX7
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0HX7 has been successfully added to your 
